AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning

 AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning

AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning

Shots:

  • AstraZeneca team up with DeepMatter to utilize its digital technologies enabled with ML and AI to improve the productivity and reproducibility of compound synthesis
  • The collaboration leverages DeepMatter’s Digital Glassware data collection and structuring technology to be used with AstraZeneca’s automated compound synthesis platform
  • Digital Glassware enables users to capture and analyze a rich array of information about their chemical reaction, leverage AI and ML to increase the certainty of producing high quality and choice of candidate drug candidates

Click here to­ read full press release/ article | Ref: DeepMatter | Image: UK Investor Magazine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post